Myeloid Growth Factors

Restricted access
  • 1

    Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:2335.

  • 2

    Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440454.

    • Search Google Scholar
    • Export Citation
  • 3

    Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1):115.

  • 4

    Fortner BV, Schwartzberg L, Tauer K. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005;13:522528.

    • Search Google Scholar
    • Export Citation
  • 5

    Gisselbrecht C, Haioun C, Lepage E. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997;25:289300.

    • Search Google Scholar
    • Export Citation
  • 6

    Timmer-Bonte JN, de Boo TM, Smit HJ. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:79747984.

    • Search Google Scholar
    • Export Citation
  • 7

    Trillet-Lenoir V, Green J, Manegold C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319324.

    • Search Google Scholar
    • Export Citation
  • 8

    Vogel CL, Wojtukiewicz MZ, Carroll RR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:11781184.

    • Search Google Scholar
    • Export Citation
  • 9

    Bui BN, Chevallier B, Chevreau C. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:26292636.

    • Search Google Scholar
    • Export Citation
  • 10

    Chevallier B, Chollet P, Merrouche Y. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:15641571.

    • Search Google Scholar
    • Export Citation
  • 11

    Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 12

    Gatzemeier U, Kleisbauer JP, Drings P. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23:393400.

    • Search Google Scholar
    • Export Citation
  • 13

    Muhonen T, Jantunen I, Pertovaara H. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol 1996;19:232234.

    • Search Google Scholar
    • Export Citation
  • 14

    Osby E, Hagberg H, Kvaloy S. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:38403848.

    • Search Google Scholar
    • Export Citation
  • 15

    Pettengell R, Gurney H, Radford JA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:14301436.

    • Search Google Scholar
    • Export Citation
  • 16

    Zinzani PL, Pavone E, Storti S. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89:39743979.

    • Search Google Scholar
    • Export Citation
  • 17

    Doorduijn JK, van der Holt B, van Imhoff GW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:30413050.

    • Search Google Scholar
    • Export Citation
  • 18

    Fossa SD, Kaye SB, Mead GM. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716724.

    • Search Google Scholar
    • Export Citation
  • 19

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 20

    Pfreundschuh M, Trumper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 21

    Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004:CD003189.

    • Search Google Scholar
    • Export Citation
  • 22

    Sung L, Nathan PC, Alibhai SM. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400411.

    • Search Google Scholar
    • Export Citation
  • 23

    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:31583167.

    • Search Google Scholar
    • Export Citation
  • 24

    Lyman GH, Dale DC, Wolff DA. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010;28:29142924.

    • Search Google Scholar
    • Export Citation
  • 25

    Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129146.

    • Search Google Scholar
    • Export Citation
  • 25

    Cosler LE, Eldar-Lissai A, Culakova E. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343351.

    • Search Google Scholar
    • Export Citation
  • 27

    Doorduijn JK, Buijt I, van der Holt B. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004;89:11091117.

    • Search Google Scholar
    • Export Citation
  • 28

    Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172179.

    • Search Google Scholar
    • Export Citation
  • 29

    Numnum TM, Kimball KJ, Rocconi RP. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:10191024.

    • Search Google Scholar
    • Export Citation
  • 30

    Timmer-Bonte JN, Adang EM, Termeer E. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290296.

    • Search Google Scholar
    • Export Citation
  • 31

    Food and Drug Administration. Filgrastim label. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16952. Accessed May 3, 2011.

    • Search Google Scholar
    • Export Citation
  • 32

    Food and Drug Administration. Pegfilgrastim label. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16131. Accessed May 3, 2011.

    • Search Google Scholar
    • Export Citation
  • 33

    Martin WG, Ristow KM, Habermann TM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:76147620.

    • Search Google Scholar
    • Export Citation
  • 34

    Tigue CC, McKoy JM, Evens AM. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185192.

    • Search Google Scholar
    • Export Citation
  • 35

    Aapro MS, Cameron DA, Pettengell R. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:24332453.

    • Search Google Scholar
    • Export Citation
  • 36

    Smith TJ, Khatcheressian J, Lyman GH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:31873205.

    • Search Google Scholar
    • Export Citation
  • 37

    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228237.

    • Search Google Scholar
    • Export Citation
  • 38

    Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park) 2003;17:813.

  • 39

    Azoulay E, Attalah H, Harf A. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001;120:16951701.

    • Search Google Scholar
    • Export Citation
  • 40

    Evens AM, Cilley J, Ortiz T. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545552.

    • Search Google Scholar
    • Export Citation
  • 41

    Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427437.

  • 42

    Aslani A, Smith RC, Allen BJ. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000;88:796803.

  • 43

    Chrischilles E, Delgado DJ, Stolshek BS. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002;9:203211.

    • Search Google Scholar
    • Export Citation
  • 44

    Lyman GH, Dale DC, Friedberg J. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:43024311.

    • Search Google Scholar
    • Export Citation
  • 45

    Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:24022409.

    • Search Google Scholar
    • Export Citation
  • 46

    Lyman GH, Morrison VA, Dale DC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:20692076.

    • Search Google Scholar
    • Export Citation
  • 47

    Morrison VA, Picozzi V, Scott S. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:4756.

    • Search Google Scholar
    • Export Citation
  • 48

    Clark OA, Lyman GH, Castro AA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:41984214.

    • Search Google Scholar
    • Export Citation
  • 49

    Berghmans T, Paesmans M, Lafitte JJ. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181188.

    • Search Google Scholar
    • Export Citation
  • 50

    Garcia-Carbonero R, Mayordomo JI, Tornamira MV. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:3138.

    • Search Google Scholar
    • Export Citation
  • 51

    Johnston E, Crawford J, Blackwell S. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:25222528.

    • Search Google Scholar
    • Export Citation
  • 52

    Green MD, Koelbl H, Baselga J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:2935.

    • Search Google Scholar
    • Export Citation
  • 53

    Kaufman PA, Paroly W, Rinaldi D. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer [abstract]. Presented at the SABCS. Abstract 1054.

    • Search Google Scholar
    • Export Citation
  • 54

    Saven A, Schwartzberg L, Kaywin P. Randomized, double-blind, phase 2, study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7570.

    • Search Google Scholar
    • Export Citation
  • 55

    Yardley DA, Burris HA III, Farley CP. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer. Clin Breast Cancer 2008;8:242248.

    • Search Google Scholar
    • Export Citation
  • 56

    Belani CP, Ramalingam S, Al-Janadi A. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7110.

    • Search Google Scholar
    • Export Citation
  • 57

    Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005;62:8387.

    • Search Google Scholar
    • Export Citation
  • 58

    Dale DC, Bonilla MA, Davis MW. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:24962502.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 336 245 23
PDF Downloads 22 12 1
EPUB Downloads 0 0 0